6.99

13.38% -1.08

After Hours: 6.96 -0.03 -0.43%

Grifols Sa Adr (GRFS)

Overview News Price History Option Chain Why GRFS Down? Discussions Forecast Stock Split Dividend History

Grifols Sa Adr stock is traded at $6.99, with a volume of 4.22M. It is down -13.38% in the last 24 hours and down -14.76% over the past month. As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

Previous Close:

$8.07

Open:

$7.07

24h Volume:

4.22M

Relative Volume:

4.29

Market Cap:

$4.75B

Revenue:

$7.42B

Net Income/Loss:

$182.73M

P/E Ratio:

24.24

EPS:

0.2884

Net Cash Flow:

$709.16M

1W Performance:

-19.66%

1M Performance:

-14.76%

6M Performance:

+1.01%

1Y Performance:

-27.64%

1-Day Range:

$6.88

$7.24

1-Week Range:

$6.88

$8.755

52-Week Range:

$5.3001

$12.15

Grifols Sa Adr Stock (GRFS) Company Profile

Name

Grifols Sa Adr

Sector

Healthcare (1180)

Industry

Drug Manufacturers - General (18)

Phone

Address

Employee

23,737

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

GRFS's Discussions on Twitter

Compare GRFS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GRFS Grifols Sa Adr	6.99	4.75B	7.42B	182.73M	709.16M	0.2713
LLY Lilly Eli Co	795.35	755.90B	40.86B	8.37B	-2.28B	9.25
NVO Novo Nordisk Adr	106.80	474.49B	39.36B	13.79B	9.83B	3.086
JNJ Johnson Johnson	155.01	353.35B	87.70B	14.68B	19.03B	6.05
ABBV Abbvie Inc	182.93	323.26B	55.53B	5.12B	15.62B	2.88
MRK Merck Co Inc	101.64	257.11B	63.17B	12.15B	14.84B	4.77

Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-24	Downgrade	Deutsche Bank	Hold → Sell
Apr-12-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-03-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-16-23	Upgrade	Barclays	Underweight → Equal Weight
Jan-18-23	Upgrade	Jefferies	Hold → Buy
Apr-08-22	Initiated	Morgan Stanley	Equal-Weight
Nov-05-21	Downgrade	Deutsche Bank	Buy → Hold
Oct-19-21	Downgrade	Barclays	Overweight → Underweight
Oct-06-21	Upgrade	Citigroup	Neutral → Buy
Jun-14-21	Upgrade	Deutsche Bank	Hold → Buy
Apr-20-21	Initiated	Deutsche Bank	Hold
Mar-23-21	Upgrade	Credit Suisse	Neutral → Outperform
Mar-11-21	Upgrade	HSBC Securities	Hold → Buy
Oct-01-20	Upgrade	Citigroup	Sell → Neutral
Jun-09-20	Downgrade	Citigroup	Neutral → Sell
Jun-09-20	Upgrade	HSBC Securities	Reduce → Hold
Mar-25-20	Downgrade	Citigroup	Buy → Neutral
Jun-27-19	Upgrade	JP Morgan	Neutral → Overweight
Feb-08-19	Downgrade	Berenberg	Buy → Hold
Oct-11-18	Upgrade	Berenberg	Hold → Buy
Jun-01-18	Initiated	Barclays	Overweight
Oct-31-17	Initiated	Citigroup	Buy
Jun-30-17	Downgrade	Goldman	Buy → Neutral
Apr-06-17	Initiated	BofA/Merrill	Buy
Jan-03-17	Upgrade	JP Morgan	Neutral → Overweight
Feb-09-16	Upgrade	Berenberg	Hold → Buy
Jan-04-16	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Dec-02-15	Downgrade	HSBC Securities	Buy → Hold
Nov-20-15	Downgrade	Berenberg	Buy → Hold
Apr-28-15	Downgrade	Berenberg	Buy → Hold

View All

Grifols Sa Adr Stock (GRFS) Latest News

Nov 28, 2024

Intravenous Solutions Market to Surpass USD 23.96 Billion by 2031 | SkyQuest Technology - Benzinga

Nov 19, 2024

Oct 16, 2024

Is it possible to buy Grifols SA ADR(GRFS) shares at a good price now? - US Post News

Oct 16, 2024

Oct 15, 2024